Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success
Also Sees Chance To Challenge Hemlibra
Executive Summary
Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: big pharma and Ukraine; new gene therapy deal for Novartis; Phase III hemophilia success for Sanofi; J&J’s Gorsky’s views on Asia innovation; and a look at pharma’s deal-making activity last year.
BioMarin Gears Up To Give Roctavian Another Go
The company is aiming for an outcomes-based payment model in the US, while it is confident the gene therapy will fare better than some others have in Europe.
Fitusiran Delay Dents Sanofi’s Hemophilia Challenge
New data show fitusiran’s promise across hemophilia A and B, but a switch to a lower dose prompted by safety concerns will delay its filing until 2024.